pleas refer disclosur section locat end
report analyst certif disclosur
akash tewari initi coverag
initi outperform rate pt impli upsid
close price
start recogn current trade premium price-to-earnings
ev/ebitda larg cap biotech price-to-earnings ev/ebitda think
justifi given best-in-class growth profil next year
importantli level think your get pipelin free
compani outstand see imag given cf
franchis get npv expect trikafta tripl regiment entri
market ex-u cf drug label expans gener continu growth
opportun come yearsw current forecast peak sale
pipelin
end dug pipelin feel aatd program
signific opportun model consensu aatd similar root
caus cf one genet mutat protein prevent properli fold
secret function vrtx small molecul aim correct
protein fold like ctfr corrector cf real shot goal treat
liver lung aatd pt unlik sirna approach treat liver diseas
initi also goe similar cf aatd find
aatd may easier er disord treat vs cf understood
street
wed like highlight point aatd program
show encourag mous data abl increas
function near normal level clear toxic build-up mutant
liver
may need potenti aatd like cf
mutant z- still retain function rel normal
ask work secret mutant management flag
didnt want place limit molecul
get drug market take aatd po get
dcf valu
see latest updat
analyst wolf research llc primarili respons research report whose name
appear first front page research report herebi certifi recommend
opinion express research report accur reflect research analyst person
view subject secur issuer ii part research analyst compens
directli indirectli relat specif recommend view contain
report
